{"DataElement":{"publicId":"7372117","version":"1","preferredName":"Treatment Cohort Study 10100 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10100 in which subsets of a defined population are identified.","longName":"TX_COHT_SDY_EC10100_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7372101","version":"1","preferredName":"10100 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"7372101v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SG06","valueDescription":"SG06: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC  2-3","ValueMeaning":{"publicId":"7373764","version":"1","preferredName":"SG06: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC  2-3","longName":"7373764","preferredDefinition":"SG06: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC  2-3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB94FCB6-0794-5985-E053-4EBD850A2D7A","latestVersionIndicator":"Yes","beginDate":"2020-07-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB94FCB6-07AD-5985-E053-4EBD850A2D7A","beginDate":"2020-07-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","deletedIndicator":"No"},{"value":"SG05","valueDescription":"SG05: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","ValueMeaning":{"publicId":"7373765","version":"1","preferredName":"SG05: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","longName":"7373765","preferredDefinition":"SG05: Phase 2, 0 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB94FCB6-07B7-5985-E053-4EBD850A2D7A","latestVersionIndicator":"Yes","beginDate":"2020-07-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB94FCB6-07D0-5985-E053-4EBD850A2D7A","beginDate":"2020-07-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","deletedIndicator":"No"},{"value":"SG08","valueDescription":"SG08: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 2-3","ValueMeaning":{"publicId":"7372102","version":"1","preferredName":"SG08: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 2-3","longName":"7372102","preferredDefinition":"SG08: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 2-3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB81F7D3-9AA8-2F79-E053-4EBD850A1FC4","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9AC1-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SG07","valueDescription":"SG07: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","ValueMeaning":{"publicId":"7372103","version":"1","preferredName":"SG07: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","longName":"7372103","preferredDefinition":"SG07: Phase 2, 1-2 Prior Regimens for Advanced Disease, PD-L1 status IHC 0-1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB81F7D3-9ACB-2F79-E053-4EBD850A1FC4","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9AE4-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SG04","valueDescription":"SG04: Safety run-in, received prior platinum therapy, PD-L1 status IHC 2-3","ValueMeaning":{"publicId":"6041939","version":"1","preferredName":"SG04: Safety run-in, received prior platinum therapy, PD-L1 status IHC 2-3","longName":"6041939","preferredDefinition":"SG04: Safety run-in, received prior platinum therapy, PD-L1 status IHC 2-3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60177EC0-20B6-6278-E053-F662850ADD6F","latestVersionIndicator":"Yes","beginDate":"2017-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9B34-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SG03","valueDescription":"SG03: Safety run-in, received prior platinum therapy, PD-L1 status IHC 0-1","ValueMeaning":{"publicId":"6041938","version":"1","preferredName":"SG03: Safety run-in, received prior platinum therapy, PD-L1 status IHC 0-1","longName":"6041938","preferredDefinition":"SG03: Safety run-in, received prior platinum therapy, PD-L1 status IHC 0-1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60177EC0-2093-6278-E053-F662850ADD6F","latestVersionIndicator":"Yes","beginDate":"2017-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9B3E-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SG02","valueDescription":"SG02: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 2-3","ValueMeaning":{"publicId":"6041937","version":"1","preferredName":"SG02: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 2-3","longName":"6041937","preferredDefinition":"SG02: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 2-3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60177EC0-2070-6278-E053-F662850ADD6F","latestVersionIndicator":"Yes","beginDate":"2017-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9B48-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"},{"value":"SG01","valueDescription":"SG01: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 0-1","ValueMeaning":{"publicId":"6041936","version":"1","preferredName":"SG01: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 0-1","longName":"6041936","preferredDefinition":"SG01: Safety run-in, cisplatin ineligible first line, PD-L1 status IHC 0-1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60177EC0-204D-6278-E053-F662850ADD6F","latestVersionIndicator":"Yes","beginDate":"2017-12-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB81F7D3-9B52-2F79-E053-4EBD850A1FC4","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB81F7D3-9A90-2F79-E053-4EBD850A1FC4","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeDescription":"7/28/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Subgroup","type":"Preferred Question Text","description":"Subgroup","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB8224B8-89FA-5363-E053-4EBD850A543F","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-07-28","modifiedBy":"SOKKERL","dateModified":"2021-08-10","changeDescription":"7/28/20 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}